Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW)
CUSIP: 68232V884
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common stock, par value $.01 per share
- Shares outstanding
- 8,133,373
- Total 13F shares
- 1,263,487
- Share change
- -468,822
- Total reported value
- $1,869,962
- Price per share
- $1.48
- Number of holders
- 19
- Value change
- -$1,075,287
- Number of buys
- 6
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 68232V884?
CUSIP 68232V884 identifies TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68232V884:
Top shareholders of TRAW - Traws Pharma, Inc. - Common stock, par value $.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Viriom, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,645,100
|
$1,480,590 | — | 03 Apr 2024 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
|
Company · 10%+ Owner |
20%
from 13D/G
|
605,531
|
$1,392,721 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
5.2%
|
421,781
|
$970,096 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
4.1%
|
330,000
|
$759,000 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13D/G
13F
|
Company |
9.9%
|
302,252
|
$462,446 | $0 | 31 Dec 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
2.2%
|
175,000
|
$402,500 | — | 31 Mar 2025 | |
| Steven M. Fruchtman |
3/4/5
|
PRESIDENT, CHIEF EXECUTIVE OFF, Director |
—
mixed-class rows
|
121,014
mixed-class rows
|
$98,282 | — | 13 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.41%
|
33,379
|
$76,775 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.41%
|
33,305
|
$76,602 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.35%
|
28,493
|
$65,534 | — | 31 Mar 2025 | |
| Abraham N. Oler |
3/4/5
|
SVP Corp Dev & Gen Counsel |
—
mixed-class rows
|
96,197
mixed-class rows
|
$36,818 | — | 07 Feb 2022 | |
| UBS Group AG |
13F
|
Company |
0.18%
|
14,323
|
$32,943 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.16%
|
13,173
|
$30,298 | — | 31 Mar 2025 | |
| Mark Patrick Guerin |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
44,755
mixed-class rows
|
$23,400 | — | 05 Feb 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.12%
|
10,071
|
$23,163 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.12%
|
9,956
|
$22,899 | — | 31 Mar 2025 | |
| Mark S. Gelder MD |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
82,667
mixed-class rows
|
$13,847 | — | 13 Mar 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.04%
|
3,261
|
$7,500 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
725
|
$1,668 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.01%
|
507
|
$1,166 | — | 31 Mar 2025 | |
| Vermillion & White Wealth Management Group, LLC |
13F
|
Company |
0%
|
96
|
$221 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
76
|
$175 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
2
|
$5 | — | 31 Mar 2025 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
—
class O/S missing
|
1
|
$1 | — | 31 Mar 2025 | |
| TPAV, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
192,696
mixed-class rows
|
— | — | 02 Apr 2025 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
164,000
|
— | — | 16 Sep 2024 | |
| Victor M. Moyo |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
class O/S missing
|
125,000
|
— | — | 02 Oct 2023 | |
| James J. Marino |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Jerome Groopman |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Peter Atadja |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Viren Mehta |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 |
Institutional Holders of Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) as of Q2 2025
As of 30 Jun 2025,
Traws Pharma, Inc. - Common stock, par value $.01 per share (TRAW) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,263,487 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vestal Point Capital, LP, Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, TWO SIGMA SECURITIES, LLC, TWO SIGMA INVESTMENTS, LP, VANGUARD GROUP INC, and BlackRock, Inc..
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
18
Q2 2025 holders
19
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.